Streetbeat News

Products Services

MNMD

Elon Musk's response to a Wall Street Journal article accusing him of using illicit drugs has sparked discussions. Meanwhile, Mind Medicine Inc. (NASDAQ:MNMD), a company developing psychedelic-inspired medicines, aims to transform mental health treatment. Despite a significant drop from its 2021 highs, MindMed's research into compounds like LSD and MDMA shows promise for treating various mental health issues without traditional pharmaceuticals. The company's stock has risen 12% in the past year but remains 94% below its peak.

Portfolio Pulse from Caleb Naysmith

February 05, 2024 | 5:04 pm

PLRX

HC Wainwright & Co. has maintained its Buy rating for Pliant Therapeutics (NASDAQ:PLRX) but lowered its price target from $52.00 to $48.00. Pliant Therapeutics' shares have fallen 3.74% in the last 24 hours to $16.75. The new price target suggests a potential upside of 186.57%. Pliant Therapeutics is developing bexotegrast for the treatment of fibrosis-related diseases.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 5:00 pm

CTLT

LLY

NVO

Eli Lilly's stock (LLY) is trading higher today, with no specific news driving the movement. Investors are anticipating the Q4 2023 results and guidance, especially regarding the weight-loss drug Zepbound. Zepbound, competing in the anti-obesity market, is priced lower than Novo Nordisk's Wegovy. Both companies are expanding production due to demand and supply constraints. Novo Nordisk is acquiring manufacturing sites from Novo Holdings, which is buying Catalent Inc. Eli Lilly's diabetes drug Mounjaro is facing limited availability due to high demand.

Portfolio Pulse from Vandana Singh

February 05, 2024 | 4:58 pm

BTAI

BioXcel Therapeutics' shares surged following the announcement that the USPTO has allowed a U.S. Patent Application for a method of treating agitation in Alzheimer's disease using dexmedetomidine oromucosal formulations.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 4:51 pm

MIRA

MIRA Pharmaceuticals' shares surged following the announcement of a research collaboration with Pharmaseed to study Ketamir's effects on major depressive disorder and PTSD patients.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 4:35 pm

AMZN

Amazon's Alexa, present in over 100 million homes and connected to 400 million devices, is set to become 'a lot smarter' with AI enhancements, despite privacy concerns. Amazon plans a paid version of Alexa for a more personalized experience, aiming to make it an indispensable part of daily life. However, this raises questions about privacy as Amazon could have unprecedented access to personal data.

Portfolio Pulse from Caleb Naysmith

February 05, 2024 | 4:34 pm

FDMT

REGN

4D Molecular Therapeutics (NASDAQ:FDMT) stock surged after positive interim data from its Phase 2 PRISM trial for 4D-150 in wet AMD patients was released. The data, presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference, showed favorable safety results and significant reduction in the annualized anti-VEGF injection rate compared to Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) Eylea. FDMT plans to start Phase 3 study in Q1 2025. FDMT shares jumped 71.58% to $30.00.

Portfolio Pulse from Vandana Singh

February 05, 2024 | 4:17 pm

CORZ

Core Scientific shares are trading higher following the announcement of their January 2024 Bitcoin production and operations updates.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 4:15 pm

AMC

LYV

RCL

Taylor Swift has filed for trademarks for 'Taylor-Con,' hinting at a potential festival for fans. The trademarks cover fan meet-ups, educational programs, and social entertainment events. This follows Swift's record-breaking 'The Eras Tour' and concert film, which saw high demand for tickets and grossed millions worldwide. Live Nation Entertainment's Ticketmaster struggled with ticket demand for Swift's tour. Additionally, fan-themed cruises organized around Swift's popularity are set for 2024, showing strong fan demand for Swift-related events.

Portfolio Pulse from Chris Katje

February 05, 2024 | 4:02 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is set to release its Q4 earnings on Feb. 5, 2024, with analysts predicting an EPS of $4.10, up from $3.76 year-over-year, and revenue of $2.51 billion, up from $2.3 billion. The company recently announced positive results from its Phase 3 trials for VX-548. Shares fell 2.1% to $424.68 recently. Analysts from JP Morgan, Truist Securities, Canaccord Genuity, RBC Capital, and HC Wainwright & Co. have updated their ratings and price targets for VRTX.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 3:59 pm